Friday, June 24, 2016 10:16:37 PM
If they can't consistently repeat it and verify it, then they can't really be said to be able to do it. There's too much instability. Is and always has been the issue. LIKELY always will be. Much like I'm beginning to think about my magic carpet, maybe it will NEVER fly.
Seymour had said they don't need the FDA as they were going to test in Australia. They needed to perform Tox because NO legitimate country will allow testing on humans with it. But when they left the FDA and met with BASi to review the Tox panel that the FDA required, they KNEW they could not manufacture sufficient material to complete Tox. Yet they started, knowing full well that the testing would never be completed. And remember, they were "laser focused" on Flucide.
Until they weren't.
Ebola came along any offered them ANOTHER high profile VIRAL disease that they could announce they were developing a treatment for. Sound familiar? Dengue, HIV, MERS, Ebola, and you know what's coming soon.
Speaking of MERS. Do you see any similarity between Seymour's statement that "we have a MERS treatment and material ready to send to the British PHE, and they've agreed to test it, but they're testing Ebola now. As soon as they ask we will send it. Almost verbatim of what he said about BASi.
And now the laser focus is no longer on Flucide, it's on Herpecide. Because the testing is shorter and they need less materials. BUT THEY'VE KNOWN THIS FOR YEARS! Why the sudden change?
Because they knew Flucide was never going to make it out of Tox.
The pattern is well established.
The 2 tells are: releases that try to conflate hiring a credible lab to perform testing with an endorsement of the NNVC platform and constantly chasing the news driven FOTM.
Where are this ebola results? MERS testing? Dr. Harris and Dengue results?
See the pattern?
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM